Bone and soft tissue sarcomas, tumors of the skinBone and soft tissue sarcomas, tumors of the skinСаркомы костей, мягких тканей и опухоли кожи2219-46142782-3687Publishing House ABV Press531EXPERIMENTAL ONCOLOGYЭКСПЕРИМЕНТАЛЬНАЯ ОНКОЛОГИЯMolecular markers in diagnostics of bone tumorsМолекулярные маркеры в диагностике опухолей костейBulytchevaI. V.БулычеваИрина Владиславовна
Russian Federation
irena@boulytcheva.comSoloviovY. N.СоловьевЮ. Н.
Russian Federation
KushlinskiyN. E.КушлинскийН. Е.
Russian Federation
FGBU N.N. Blokhin Russian Cancer Research CenterФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН0308201353737803022022Copyright ©; 2013, Bulytcheva I.V., Soloviov Y.N., Kushlinskiy N.E.Copyright ©; 2013, Булычева И.В., Соловьев Ю.Н., Кушлинский Н.Е.2013Bulytcheva I.V., Soloviov Y.N., Kushlinskiy N.E.Булычева И.В., Соловьев Ю.Н., Кушлинский Н.Е.https://creativecommons.org/licenses/by/4.0https://sarbon.abvpress.ru/jour/article/view/531

There has been tremendous progress in the last decade in understanding of the behavior and molecular pathogenesis of sarcomas, which may ultimately lead to more effective therapy and prognostification for these rare malignancies. Bone and soft tissue sarcomas are uncommon group of tumors, they are histologically, behaviorally, and genetically diverse, and their pathogenesis is poorly understood. The increasing role of molecular diagnostics is up to date, this knowledge relates to the potential role of newer targeted therapies. The importance of multidisciplinary care, integration of histologic, molecular, radiographic and clinical data in the management of bone sarcomas is difficult to overestimate.

Генетический паспорт злокачественных опухолей в значительной мере предопределяет клиническое прогрессирование и прогноз онкологического заболевания. Современная морфологическая диагностика сарком костей невозможна без дополнительных методов исследования. Среди диагностических и прогностических критериев все большее значение приобретает иммунофенотипирование. новые молекулярные мишени (Bax, EGFR, Flt-1/ VEGFR1 Ab-1, Her-2/neu, Cox-2, p53,VEGF) находятся под пристальным вниманием исследователей для выявления агентов эффективной таргетной терапии.

опухоли костеймолекулярные маркерыпатологияbone tumorsmolecular markerspathologyBovee J.V.M.G., Hogendoom P.C.W., Wunder J.S. et al. Cartilage tumors and bone development: molecular pathology and possible theraputic targets. Nat. Rev. Cancer. 2010, v. 10, p. 481-488.Cho H.Y., Lee M., Takei H. et al. Immunohistochemical comparison of chordoma with chondrosarcoma, myxopapillary ependymoma, chordoid meningioma. Appl. Immunoch- istochem. Mol. Morphol. 2009, v. 17, No. 2, p. 131-138.Folpe A.L., Goldblum J.R., Rubin B.P. et al: Morpholpogic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am. J. Surg. Path. 2005, v. 29, p. 1025-1035.Gafney R., Unni K.K., Sim F.H. et al. Follow-up study of long-term survivous of osteosarcoma in the pre-chemotherapy era. Hum. Pathol. 2006, v. 37, p. 1009-1014.Hoch B.L., Nielsen G.P., Liebsh N.G. et al. Base of skull Chordomas in children and adolescents; a clinicopathologic study of 73 cases. Am. J. Surg. Pathol. 2006, v. 30, No. 70, p. 811-818.Huse J.T, Pasha T.L., Zhang P.J. D2-40 functions as an effective chondroid marker distinguishing true chondroid tumors from chordoma. Acta Neuropathol. 2007, v. 113, No. 1, p. 87-94.Klein M.J., Siegal G.P. Osteosarcoma: anatomic and histologic variants. Am. J. Clin. Pathol. 2006, v. 125, p. 555-581.Kyriakos M., Totty W.G., Lenke L.G. Giant vertebral notochordal rest: a lesion distinct from chordoma: discussion of an evolving concept. Am. J. Surg. Pathol. 2003, v. 27, No. 3, p. 396-406.Longhi A., Erani C., De Paolois M. et al: Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat. Rev. 2006, v. 32, p. 423-436.Paulussen M., Bielack S., Jurgens H. et al: Ewing’s sarcoma of the bone: EMSO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 2009, v. 20, iv, p. 140-142.Ragland B.D., Bell W.C., Lopez R.R. et al. Cytogenetics and molecular biology of osteosarcoma. Lab. Invest. 2002, v. 82, p. 365-373.Sandberg A.A., Bridge J.A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet. Cytogenet. 2003, v. 145, p. 1-30.Santa Cruz D.J. Seminars in Diagnostic Pathology. Orthopaedic pathology. 2011, v. 28, No. 1.The Skeletal lesions Interobserver Correlation among Expert Diagnosicians (SLICED) Study Group. Reliability of histopathologic and radiologic grading of cartilaginous neoplasms in long bones. J. Bone Joint Surg. Am. 2007, v. 89, p. 2113-2123.Vasishta R.K., Gupta N., Kakkar N. et al. Prognostic and predictive value of c-erbB2 overexpression in osteogenic sarcoma. J. Cancer Res. Ther. 2006, v. 2, p. 20-23.Tsai J.Y., Aviv H., Benevenia J. et al. HER-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis. Cancer Invest. 2004, v. 22, p. 16-24.Tsuchiya T, Sekine K.-ichi, Hinohara Sh.-ichi et al. Analysis of the p16INK4, p14ARF, p16, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing’s sarcoma. Cancer Genet. Cytogenet. 2000, v. 154, p. 91-98.Weiss K.R., Cooper G.M., Jadlowiec J.A. et al. VEGF and BMP expression in mouse osteosarcoma cells. Clin. Orthop. Relat. Res. 2006, v. 450, p. 111-117.